Dabigatran vs. Placebo in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy: A Randomized, Double-Blind, Phase II Trial

Study Questions:

What are the safety and indicators of efficacy of the novel oral direct thrombin inhibitor, dabigatran, after an acute coronary syndrome?